A Comparison of the Effects of Tiotropium (18 Mcg) Inhalation Capsule q.d. and Salmeterol (50 Mcg) Inhalation Aerosol b.i.d. on Arterial Blood Gases in a Double-blind, Double-dummy, 4-week Crossover Study in Patients With Chronic Obstructive Pulmonary Disease (COPD).
- NCT00274534
- PHASE3
- INTERVENTIONAL
Last updated: 2013-11-05
Purpose of Trial
To evaluate changes in PaO2 following inhalation of Tiotropium by HandiHaler compared to Salmeterol MDI in patients with moderate to severe COPD.
This study is for people with
Pulmonary Disease, Chronic Obstructive
Interventions being studied
Tiotropium
Salmeterol
ELIGIBILITY
Gender: ALL
Age: 50+
Healthy Volunteers: No
2 Locations
Hines
Hines Veterans Administration Hospital
Illinois, United States
Richmond
Hunter Holmes McGuire Medical Center
Virginia, United States
Primary Contact(s)
Boehringer Ingelheim
Data obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Learn more at
ClinicalTrials.gov